DelveInsight’s, “Retinoic Acid Receptor (RARs) Agonist - Pipeline Insight, 2022,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinoic Acid Receptor (RARs) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Retinoic Acid Receptor (RARs) Agonist: Overview
Retinoic acid receptors (RARs) are nuclear hormone receptors of the NR1B class, which function as heterodimers with retinoid X receptors (RXRs). The retinoic acid receptors (RARα, RARβ, and RARγ) are members of the nuclear receptor superfamily. Compounds which bind to and activate the RARs are termed retinoids and comprise both natural retinol (Vitamin A) metabolites and synthetic analogs. Upon binding of an agonist ligands to RAR results in dissociation of corepressor and recruitment of coactivator protein that, promotes transcription of the downstream target gene into mRNA and eventually protein. Several Retinoic Acid Receptors (RAR) agonists have therapeutic activity against a variety of cancer types. RAR agonists presenting novel structural and chemical features could therefore open new avenues for the discovery of leads against breast, lung and prostate cancer or leukemia.
The companies and academics are working to assess challenges and seek opportunities that could influence Retinoic Acid Receptor (RARs) Agonist R&D. The therapies under development are focused on novel approaches for Retinoic Acid Receptor (RARs) Agonist.
This segment of the Retinoic Acid Receptor (RARs) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Retinoic Acid Receptor (RARs) Agonist Emerging Drugs
Palovarotene: Clementia Pharmaceuticals (Ipsen)
Palovarotene is a RARγ agonist being developed as a potential treatment for patients with ultra-rare and debilitating bone diseases, including fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other conditions including dry eye disease. Palovarotene had received rare pediatric disease and breakthrough therapy designations for the treatment of an ultra-rare bone disorder.
IRX 5183: Allergan (AbbVie)
IRX 5183 is a selective, orally available, third generation vitamin A derivative and first in class Retinoic Acid Receptor alpha (RARα) agonist. IRX 5183 is a drug that is designed to cause cancer cells to mature and then die. The drug is in Phase I/II clinical development for the treatment of cancer.
Further product details are provided in the report……..
This segment of the report provides insights about the different Retinoic Acid Receptor (RARs) Agonist drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 15+ key companies which are developing the Retinoic Acid Receptor (RARs) Agonist. The companies which have their Retinoic Acid Receptor (RARs) Agonist drug candidates in the most advanced stage, i.e. Phase III include, Clementia Pharmaceuticals (Ipsen).
DelveInsight’s report covers around 15+ products under different phases of clinical development like
Retinoic Acid Receptor (RARs) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Retinoic Acid Receptor (RARs) Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Retinoic Acid Receptor (RARs) Agonist drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Retinoic Acid Receptor (RARs) Agonist: Overview
Pipeline Therapeutics
Therapeutic Assessment
Retinoic Acid Receptor (RARs) Agonist – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Retinoic Acid Receptor (RARs) Agonist Collaboration Deals
Late Stage Products (Phase III)
Palovarotene: Clementia Pharmaceuticals (Ipsen)
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Tretinoin topical: Avecho Biotechnology
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
IRX 5183: Allergan (AbbVie)
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Fenretinide intravenous: SciTech Development
Drug profiles in the detailed report…..
Inactive Products
Retinoic Acid Receptor (RARs) Agonist Key Companies
Retinoic Acid Receptor (RARs) Agonist Key Products
Retinoic Acid Receptor (RARs) Agonist- Unmet Needs
Retinoic Acid Receptor (RARs) Agonist- Market Drivers and Barriers
Retinoic Acid Receptor (RARs) Agonist- Future Perspectives and Conclusion
Retinoic Acid Receptor (RARs) Agonist Analyst Views
Retinoic Acid Receptor (RARs) Agonist Key Companies
Appendix
List of Table
Table 1: Total Products for Retinoic Acid Receptor (RARs) Agonist
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Retinoic Acid Receptor (RARs) Agonist
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Clementia Pharmaceuticals (Ipsen)
• Nippon Shinyaku
• Bausch Health Companies
• Galderma
• Avecho Biotechnology
• Allergan (AbbVie)
• Celgene
• SciTech Development
• Polaryx Therapeutics
